These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21153814)

  • 1. Lymphadenectomy exacerbates tumor growth while lymphadenectomy plus the adoptive transfer of autologous cytotoxic cells and low-dose cyclophosphamide induces regression of an established murine fibrosarcoma.
    Maglioco A; Machuca D; Mundiñano J; Cabrera G; Camicia G; Bruzzo J; Camerano G; Costa H; Ruggiero RA; Dran GI
    Cancer Immunol Immunother; 2011 Mar; 60(3):389-99. PubMed ID: 21153814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-induced suppression of antitumor reactivity and depression of TCRzeta expression in tumor-draining lymph node lymphocytes: possible relationship to the Th2 pathway.
    Fu EJ; Arca MJ; Hain JM; Krinock R; Rado J; Cameron MJ; Chang AE; Sondak VK
    J Immunother; 1997 Mar; 20(2):111-22. PubMed ID: 9087383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern.
    Li Q; Carr AL; Donald EJ; Skitzki JJ; Okuyama R; Stoolman LM; Chang AE
    Cancer Res; 2005 Feb; 65(3):1063-70. PubMed ID: 15705908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
    Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
    J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.
    Peng L; Kjaergäard J; Plautz GE; Awad M; Drazba JA; Shu S; Cohen PA
    J Immunol; 2002 Nov; 169(9):4811-21. PubMed ID: 12391191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunological mouse mutants nude (nu) and rhino (hrrh) generate cytotoxic effector cells following adoptive immunotherapy but fail to reject a transplanted tumor.
    Evans R; Duffy TM; Shultz LD
    Cancer Immunol Immunother; 1988; 26(1):35-42. PubMed ID: 3257902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy.
    Li Q; Carr A; Ito F; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2003 May; 63(10):2546-52. PubMed ID: 12750278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific granulocyte/macrophage colony-stimulating factor and interferon gamma secretion is associated with in vivo therapeutic efficacy of activated tumor-draining lymph node cells.
    Aruga A; Shu S; Chang AE
    Cancer Immunol Immunother; 1995 Nov; 41(5):317-24. PubMed ID: 8536278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan.
    Mortara L; Balza E; Sassi F; Castellani P; Carnemolla B; De Lerma Barbaro A; Fossati S; Tosi G; Accolla RS; Borsi L
    Eur J Immunol; 2007 Dec; 37(12):3381-92. PubMed ID: 18022863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma.
    Naito K; Oka T; Nomi S; Yamagishi H; Kahan BD
    Jpn J Cancer Res; 1989 Nov; 80(11):1119-26. PubMed ID: 2514172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.
    Plautz GE; Inoue M; Shu S
    Cell Immunol; 1996 Aug; 171(2):277-84. PubMed ID: 8806798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
    Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.
    Li Q; Teitz-Tennenbaum S; Donald EJ; Li M; Chang AE
    J Immunol; 2009 Sep; 183(5):3195-203. PubMed ID: 19667089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Donor cell cycling, trafficking, and accumulation during adoptive immunotherapy for murine lung metastases.
    Skitzki J; Craig RA; Okuyama R; Knibbs RN; McDonagh K; Chang AE; Stoolman LM
    Cancer Res; 2004 Mar; 64(6):2183-91. PubMed ID: 15026361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10.
    Tao H; Lu L; Xia Y; Dai F; Wang Y; Bao Y; Lundy SK; Ito F; Pan Q; Zhang X; Zheng F; Shu G; Fang B; Jiang J; Xia J; Huang S; Li Q; Chang AE
    Eur J Immunol; 2015 Apr; 45(4):999-1009. PubMed ID: 25545618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide.
    Komichi H; Smith S; Kahan BD
    Arch Surg; 1992 Dec; 127(12):1417-23. PubMed ID: 1365687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ex vivo stimulation of tumor-draining lymph node cells from lung cancer patients: a potential resource for adoptive immunotherapy.
    Shan B; Li Q; He M; He Y
    Cell Mol Immunol; 2008 Aug; 5(4):307-13. PubMed ID: 18761819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.